HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lachmann, P. J. Articles by Müller-Eberhard, H. J. Search for Related Content PubMed Articles by Lachmann, P. J. Articles by Müller-Eberhard, H. J.

The Demonstration in Human Serum of "Conglutinogen-Activating Factor" and its Effect on the Third Component of Complement^1,2,

From the Department of Experimental Pathology, Scripps Clinic and Research Foundation, La Jolla, California

Abstract

It has been found that the intermediate complex EAC'1a,4,2a,3, if built-up with purified complement components, fails to react with bovine conglutinin. The participation of a further serum factor, distinct from the hitherto described complement components, is required for the reactivity toward conglutinin to be acquired. To this factor the name conglutinogen-activating factor (or KAF) has been provisionally given. KAF has been partially purified from human serum and has been found to be a -globulin with a molecular weight of approximately 100,000. It appears to be present in serum in very small quantities. KAF reacts specifically with bound C'3 and no other complement components are necessary for the reaction to occur. The nature of the reaction on bound C'3 is unclear, but it seems more likely that KAF produces some change, possibly enzymatically, in the bound C'3 molecule than that KAF is bound stoichiometrically on the alexinated complex. Besides activating the conglutinogen, KAF makes bound C'3 very much more sensitive to enzymatic attack.

Footnotes

¹ This is publication no. 247 from the Department of Experimental Pathology, Scripps Clinic and Research Foundation, La Jolla, California.

² This work was supported by United States Public Health Service Grant 7007-01 and by American Heart Association Grant 65-G-166.

³ Present address: Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, England. A travel grant by the Wellcome Trust is gratefully acknowledged.

This article has been cited by other articles:

				C. Alper and D Balavitch Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement) Science, March 26, 1976; 191(4233): 1275 - 1276. [Abstract] [PDF]